Table of Content



1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Therapeutics
3.3. Snippet by Route of Administration
3.4. Snippet by End user
3.5. Snippet by Region

4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. Increasing clinical trials
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side effects of Antiviral drug
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Influenza Type A*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Influenza Type B
7.4. Influenza Type C
7.5. Influenza Type D

8. By Therapeutics
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
8.1.2. Market Attractiveness Index, By Therapeutics
8.2. Medication*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. Antiviral Agents
8.2.2.1.1.1. Baloxavir
8.2.2.1.1.2. Oseltamivir
8.2.2.1.1.3. Peramivir
8.2.2.1.1.4. Others
8.2.2.2. Anti-Microbial Agents
8.2.2.2.1.1. Rimantadine
8.2.2.2.1.2. Amantadine
8.2.2.2.1.3. Others
8.3. Vaccines
8.3.1.1. Inactivated Influenza Vaccine (IIV)
8.3.1.2. Live Attenuated Influenza Vaccine (LAIV)
8.3.1.3. Others

9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By route of administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Inhaled
9.4. Injectables

10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals and Clinics*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Centers
10.4. Others

11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles
13.1. Merck KGaA
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Santa Cruz Biotechnology, Inc.
13.3. Biosynth
13.4. Teva Pharmaceuticals USA, Inc.
13.5. Biorbyt Ltd.
13.6. Thermo Fisher Scientific Inc.
13.7. Steris Healthcare PVT Ltd.
13.8. Genentech, Inc.
13.9. Lupin Pharmaceuticals, Inc.
13.10. BioCryst Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE

14. Appendix
14.1. About Us and Services
14.2. Contact Us